An Open Label pH Comparison of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients

AstraZeneca

Status and phase

Completed

Phase 4

Conditions

Barrett's Esophagus

Treatments

Drug: Lansoprazole

Drug: Esomeprazole

Study type

Interventional

Funder types

Industry

Identifiers

NCT00352261

D9612L00082

Details and patient eligibility

About

The purpose of the study is to compare the treatment of esomeprazole 40 mg once daily and lansoprazole 30 mg once daily in controlling intragastric pH in Barrett's Esophagus patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Documented history (within 2 yrs of histologically proven BE;
Aged 18-70 (inclusive);
Willing and able to comply with all study procedures

Exclusion criteria

Signs of clinically significant GI bleeding within 3 days prior to randomization;
History of gastric or esophageal surgery;
Clinically significant illness within 2 weeks prior to first dose of study drug or during study